-

Transgene: Combined General Meeting of May 27, 2020

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 27, 2020) at 10:00 a.m. at the Company's headquarters (400 boulevard Gonthier d'Andernach - Parc d'Innovation - 67400 Illkirch-Graffenstaden) chaired by Philippe Archinard, Chairman and CEO, to approve the company financial statements for the year ended December 31, 2019 and to vote the others resolutions submitted to their approval. As a result of restrictions placed on the movement and gatherings of persons in the context of the COVID-19 pandemic, this General Meeting was held behind closed doors without the physical presence of its shareholders.

At the Combined General Meeting, the shareholders have:

- renewed the mandates of the following Board Members: Philippe Archinard, Benoît Habert, Marie Landel, Maya Saïd and TSGH, Transgene’s majority shareholder, represented by Dominique Takizawa;
- voted the other resolutions submitted, in accordance with the recommendations of the Board of Directors.

Detailed voting results are available on Transgene's website, under the heading Investors > General Meeting.

In the board meeting following the Combined General Meeting, the board of directors:

- confirmed Mr Philippe Archinard, Mrs Marie Landel and Mr Benoît Habert in their respective mandates as Chairman of the Board, Chairman of the Audit Committee and Chairman of the Compensation Committee;
- implemented the reduction of the nominal value from 1.00 euro to 0.50 euro per share. 

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Media:
Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
+ 44 (0)20 7638 9571
transgene@citigatedewerogerson.com

Transgene

BOURSE:TNG

Release Versions

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Media:
Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
+ 44 (0)20 7638 9571
transgene@citigatedewerogerson.com

Social Media Profiles
More News From Transgene

Transgene Announces Upcoming Investor Meetings

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below. Transgene will meet institutional investors at the 13th Annual LifeSci Advisors Corporate Access Event in San Francisco from January 8 to 10, 2024, in conjunction with the J.P. Morgan Healthcare conference. The Company will also attend: 27th ODDO BHF Forum (virtual): January 15-16, 2024; Invest...

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of it...

Transgene Reports Business Update and Q3 2023 Financial Position

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its financial position for the quarter ending September 30, 2023. During the third quarter of 2023, Transgene’s clinical-stage immunotherapy portfolio continued to advance. Notable progress included the treatment of the first patient in the Part B of Phase I trial assess...
Back to Newsroom